Medtronic is projected to report fiscal fourth-quarter revenue of $9.62 billion and earnings per share of $1.54, with the current stock price of $73.73 trading significantly below the average analyst target of $106.10.
The primary focus for investors this quarter is organic revenue growth, particularly as the company navigates the strategic spin-off of its MiniMed Diabetes business.
Supporting this growth is sustained demand in the Cardiovascular portfolio, led by the Affera pulsed field ablation system and international adoption of the 780G insulin pump. However, analysts are monitoring margin compression stemming from recent bolt-on acquisitions and one-time separation costs that may weigh on the bottom-line outlook.